Summary

The treatment of non-small cell lung cancer (NSCLC) presents several challenges. Practice guidelines are based on limited evidence, and are often unclear and subject to multiple interpretations. Determining when mediastinal lymph nodes should be sampled, and how to best treat stage III disease, presents a particular challenge. Better treatment outcomes are needed.